Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: Utilization of a more suitable medium for in-vitro dissolution study

Yoshitsugu Fujioka, Keitaro Kadono, Yasuko Fujie, Yukiko Metsugi, Ken ichi Ogawara, Kazutaka Higaki, Toshikiro Kimura

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The in-vivo absorbability of drugs categorized into the biopharmaceutics classification system (BCS) class II is very difficult to be predicted because of the large variability in the absorption and/or dissolution kinetics and the lack of an adequate in-vitro system for evaluating the dissolution behavior. We tried to predict the in-vivo absorption kinetics of griseofulvin, categorized into BCS class II, orally administrated as powders into rats, based on Gastrointestinal-Transit-Absorption model (GITA model), consisting of the absorption, dissolution and GI-transit processes. Using the dissolution rate constants (kdis) of griseofulvin obtained with JP 1st solution, JP 2nd solution, FaSSIF, FeSSIF and modified SIBLM as a medium, simulation lines were not able to describe the observed mean plasma profile at all. On the other hand, a calculated line provided by employing kdis obtained with MREVID 2 (medium reflecting in-vivo dissolution 2), a new medium, was in better agreement with the observed mean plasma profile than existing media, indicating that the utilization of adequate kdis value made it possible to predict the in-vivo absorption kinetics of drugs classified into BCS class II based on GITA model and that MREVID 2 could be a useful medium for describing the in-vivo dissolution kinetics.

Original languageEnglish
Pages (from-to)222-228
Number of pages7
JournalJournal of Controlled Release
Volume119
Issue number2
DOIs
Publication statusPublished - Jun 1 2007

Fingerprint

Biopharmaceutics
Gastrointestinal Transit
Griseofulvin
Pharmaceutical Preparations
Powders
Pharmacokinetics
In Vitro Techniques
Gastrointestinal Absorption

Keywords

  • Biopharmaceutics classification system class II
  • In-vitro dissolution study
  • Oral absorption
  • Powder
  • Prediction

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model : Utilization of a more suitable medium for in-vitro dissolution study. / Fujioka, Yoshitsugu; Kadono, Keitaro; Fujie, Yasuko; Metsugi, Yukiko; Ogawara, Ken ichi; Higaki, Kazutaka; Kimura, Toshikiro.

In: Journal of Controlled Release, Vol. 119, No. 2, 01.06.2007, p. 222-228.

Research output: Contribution to journalArticle

Fujioka, Yoshitsugu ; Kadono, Keitaro ; Fujie, Yasuko ; Metsugi, Yukiko ; Ogawara, Ken ichi ; Higaki, Kazutaka ; Kimura, Toshikiro. / Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model : Utilization of a more suitable medium for in-vitro dissolution study. In: Journal of Controlled Release. 2007 ; Vol. 119, No. 2. pp. 222-228.
@article{039ad634c3a8408a89e294566d1c1803,
title = "Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: Utilization of a more suitable medium for in-vitro dissolution study",
abstract = "The in-vivo absorbability of drugs categorized into the biopharmaceutics classification system (BCS) class II is very difficult to be predicted because of the large variability in the absorption and/or dissolution kinetics and the lack of an adequate in-vitro system for evaluating the dissolution behavior. We tried to predict the in-vivo absorption kinetics of griseofulvin, categorized into BCS class II, orally administrated as powders into rats, based on Gastrointestinal-Transit-Absorption model (GITA model), consisting of the absorption, dissolution and GI-transit processes. Using the dissolution rate constants (kdis) of griseofulvin obtained with JP 1st solution, JP 2nd solution, FaSSIF, FeSSIF and modified SIBLM as a medium, simulation lines were not able to describe the observed mean plasma profile at all. On the other hand, a calculated line provided by employing kdis obtained with MREVID 2 (medium reflecting in-vivo dissolution 2), a new medium, was in better agreement with the observed mean plasma profile than existing media, indicating that the utilization of adequate kdis value made it possible to predict the in-vivo absorption kinetics of drugs classified into BCS class II based on GITA model and that MREVID 2 could be a useful medium for describing the in-vivo dissolution kinetics.",
keywords = "Biopharmaceutics classification system class II, In-vitro dissolution study, Oral absorption, Powder, Prediction",
author = "Yoshitsugu Fujioka and Keitaro Kadono and Yasuko Fujie and Yukiko Metsugi and Ogawara, {Ken ichi} and Kazutaka Higaki and Toshikiro Kimura",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.jconrel.2007.03.002",
language = "English",
volume = "119",
pages = "222--228",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model

T2 - Utilization of a more suitable medium for in-vitro dissolution study

AU - Fujioka, Yoshitsugu

AU - Kadono, Keitaro

AU - Fujie, Yasuko

AU - Metsugi, Yukiko

AU - Ogawara, Ken ichi

AU - Higaki, Kazutaka

AU - Kimura, Toshikiro

PY - 2007/6/1

Y1 - 2007/6/1

N2 - The in-vivo absorbability of drugs categorized into the biopharmaceutics classification system (BCS) class II is very difficult to be predicted because of the large variability in the absorption and/or dissolution kinetics and the lack of an adequate in-vitro system for evaluating the dissolution behavior. We tried to predict the in-vivo absorption kinetics of griseofulvin, categorized into BCS class II, orally administrated as powders into rats, based on Gastrointestinal-Transit-Absorption model (GITA model), consisting of the absorption, dissolution and GI-transit processes. Using the dissolution rate constants (kdis) of griseofulvin obtained with JP 1st solution, JP 2nd solution, FaSSIF, FeSSIF and modified SIBLM as a medium, simulation lines were not able to describe the observed mean plasma profile at all. On the other hand, a calculated line provided by employing kdis obtained with MREVID 2 (medium reflecting in-vivo dissolution 2), a new medium, was in better agreement with the observed mean plasma profile than existing media, indicating that the utilization of adequate kdis value made it possible to predict the in-vivo absorption kinetics of drugs classified into BCS class II based on GITA model and that MREVID 2 could be a useful medium for describing the in-vivo dissolution kinetics.

AB - The in-vivo absorbability of drugs categorized into the biopharmaceutics classification system (BCS) class II is very difficult to be predicted because of the large variability in the absorption and/or dissolution kinetics and the lack of an adequate in-vitro system for evaluating the dissolution behavior. We tried to predict the in-vivo absorption kinetics of griseofulvin, categorized into BCS class II, orally administrated as powders into rats, based on Gastrointestinal-Transit-Absorption model (GITA model), consisting of the absorption, dissolution and GI-transit processes. Using the dissolution rate constants (kdis) of griseofulvin obtained with JP 1st solution, JP 2nd solution, FaSSIF, FeSSIF and modified SIBLM as a medium, simulation lines were not able to describe the observed mean plasma profile at all. On the other hand, a calculated line provided by employing kdis obtained with MREVID 2 (medium reflecting in-vivo dissolution 2), a new medium, was in better agreement with the observed mean plasma profile than existing media, indicating that the utilization of adequate kdis value made it possible to predict the in-vivo absorption kinetics of drugs classified into BCS class II based on GITA model and that MREVID 2 could be a useful medium for describing the in-vivo dissolution kinetics.

KW - Biopharmaceutics classification system class II

KW - In-vitro dissolution study

KW - Oral absorption

KW - Powder

KW - Prediction

UR - http://www.scopus.com/inward/record.url?scp=34248582287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248582287&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2007.03.002

DO - 10.1016/j.jconrel.2007.03.002

M3 - Article

C2 - 17442444

AN - SCOPUS:34248582287

VL - 119

SP - 222

EP - 228

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -